Pressing Pause on Psychedelic Cash

Analysing the Challenges in Psychedelic Drug Development Through Investment Trends

Adrienne Rivlin

Read more

Related Insights

Life Sciences & Pharma

AI and Biopharma: New Solutions Emerging Across the US Value Chain

December 6, 2024

Executive Insights

Life Sciences & Pharma

From Niche to Widespread Use: The Turning Point for Radiotherapeutics

November 12, 2024

Executive Insights

Life Sciences & Pharma

Understanding the Inflation Reduction Act Negotiation Prices After the Dust Has Settled

September 27, 2024

Executive Insights

Post-Merger Integration

Approaches to Building the Leadership Team in a Merger Integration

May 16, 2024

Life Sciences & Pharma

Value Story and Cross-Stakeholder Action Plan for Oncology Reimbursement

May 8, 2024

A big pharma company wanted to enable change in payer attitudes to increase the acceptance of patient-reported outcomes (PROs) and of endpoints beyond…

Medical Equipment

Collaborating for a Robust Medical Device Reimbursement Pathway in India

April 2, 2024